awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36682843-1FF788F0-42D1-47D4-8868-F16702421A90
Q36682843-1FF788F0-42D1-47D4-8868-F16702421A90
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36682843-1FF788F0-42D1-47D4-8868-F16702421A90
Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
P2860
Q36682843-1FF788F0-42D1-47D4-8868-F16702421A90
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36682843-1FF788F0-42D1-47D4-8868-F16702421A90
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
23acecfe828d6e6713b7040ea18c6904a3007517
P2860
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.